Last reviewed · How we verify
ON 01910.Na and oxaliplatin
At a glance
| Generic name | ON 01910.Na and oxaliplatin |
|---|---|
| Also known as | diaminocyclohexane oxalatoplatinum, oxalatoplatin, oxalatoplatinum, Eloxatin |
| Sponsor | Traws Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin (PHASE1)
- Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ON 01910.Na and oxaliplatin CI brief — competitive landscape report
- ON 01910.Na and oxaliplatin updates RSS · CI watch RSS
- Traws Pharma, Inc. portfolio CI